

PledPharma presents PledOx®'s global phase III program at ASCO

PledPharma AB (publ) announces that the company's global phase III program, POLAR, will be presented at a poster session during the American Society of Clinical Oncology (ASCO Annual meeting) May 31-June 4 in Chicago.

ASCO is the most prominent global conference within the field of oncology.

The title of the presentation is: The Global POLAR program: Two pivotal placebo-controlled studies of calmagafodipir used on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy (CIPN).

It will be presented by one of the Coordinating Investigators of the POLAR M study, Dr Maryam Lustberg, The Ohio State Comprehensive Cancer Center, Columbus, OH, USA and Dr Stefan Carlsson, Chief Medical Officer at PledPharma.

"We are proud to have been selected as one of the presenters at ASCO. I see presenting the study at the most prominent oncology conference as a confirmation of the interest in PledOx®'s potential and the unmet medical need in this patient population." says Nicklas Westerholm, CEO, PledPharma AB.

Meeting information:

Abstract number: TPS3616

Poster Session: Gastrointestinal (Colorectal) Cancer, 6/3/2019, 8:00 AM-11:00 AM

Poster Board: 107b

Contacts

Nicklas Westerholm, CEO, phone: +46 73 354 20 62

nicklas.westerholm@pledpharma.se

Yilmaz Mahshid, CFO, phone: +46 72 231 68 00

yilmaz.mahshid@pledpharma.se

About Us

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company's most advanced project **PledOx®** is being developed to prevent nerve damage associated with chemotherapy. A global phase III program is ongoing. The drug candidate **Aladote®** is being developed to reduce the risk of acute liver injury associated with acetaminophen poisoning. A proof of principle study has been successfully completed and the design of the next study is being finalised. Aladote® has been granted Orphan Drug Designation in

Press release
31 May 2019 08:00:00 CEST



the US. PledPharma (STO:PLED) is listed on Nasdaq First North. Erik Penser Bank acts Certified Adviser (www.penser.se). For further information, please see www.pledpharma.se

Attachments

[PledPharma presents PledOx®'s global phase III program at ASCO](#)